Collaboration Responsibilities. SUBGRANTEE shall participate in the Continuum of Care (CoC) Collaborative Committee meetings, EO Implementation Team meetings, and other meetings related to the Governor’s Emergency Declaration, upon request of the Grant Manager. SUBGRANTEE shall participate in the CoC’s Coordinated Entry System, abiding by and adhering to the CoC’s Coordinated Entry Policies and Procedures. All activities conducted under this Contract must be Housing Focused. “Housing Focused” activities are defined as activities that seek to lower barriers for people experiencing homelessness or housing instability. Activities conducted under this Contract may not screen participants out solely on the basis of certain behavioral, psychological, physiological, citizenship or immigration status or economic preconditions. Housing Focused services must ensure that the safety and support of both staff and clients are paramount. This is accomplished through a focus on ensuring safety by managing behaviors that pose a risk to health and safety rather than implementing blanket exclusions based on a past diagnosis or current behavioral health symptoms that do not pose a direct risk to community safety. Furthermore, SUBGRANTEE must actively coordinate services and supports for helping people exit homelessness and make efforts to reduce the barriers to re-housing individuals and families in their community.
Collaboration Responsibilities. The parties shall collaborate to develop VACCINE for commercialization according to the terms of this AGREEMENT. INO shall be responsible for conducting all research & development (the “R&D”). The R&D shall include all research and pre-clinical studies. All R&D studies related to and in support of clinical trials in the TERRITORY shall be funded entirely by VGXI. VGXI shall be responsible for the preparation of all dossiers and data, which are essentially required for conducting R&D in the TERRITORY. Furthermore, for the avoidance of doubt, VGXI under the guidance of the JDC shall have the right to pursue any DNA flu vaccine that is an INO LICENSED PRODUCT in the FIELD and in the TERRITORY, which includes DNA component(s) that is or are a subset of the SynConTM universal flu vaccine.
Collaboration Responsibilities. The parties shall collaborate to develop the VACCINE for commercialization according to the terms of this AGREEMENT. INO shall be responsible for conducting all research & development (the “R&D”). The R&D shall include all research and pre-clinical studies. All R&D studies related to and in support of pre-clinical trials, and Phase 1 and Phase 2 clinical studies shall be funded entirely by VGXI. VGXI shall be responsible for the preparation of all dossiers and data, which are essentially required for conducting R&D in the TERRITORY. VGXI will have the right to conduct studies related to the VACCINE in any desired place in the TERRITORY under the direction of the JDC.
Collaboration Responsibilities. The CUA group will maintain a commitment to the management and op- eration of the Collaboration, much in the manner we have done in previous collaborations.
Collaboration Responsibilities
